Industry Research Reports

Home > Reports > Medical Care > Global Antibody and Recombinant Protein CDMO Market Research Report 2025

Global Antibody and Recombinant Protein CDMO Market Research Report 2025

Industry: Medical Care

Published Date: 2025-01-16

Pages: 105 Pages

Report ld: 3454464

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Antibody and Recombinant Protein CDMO Market Size(US$)

CAGR 2025-2031

Market Size,2031

USD 94,330

Million

Market Snapshot

Market Size in 2025 (Value)

US$ 62,860 million

Market Forecast in 2031(Value)

US$ 94,330 million

CAGR

Years Considered

2020-2031

Base Year

2025

Forecast Period

2025-2031

Source: Secondary research, interviews with experts, and QYResearch analysis

The global market for Antibody and Recombinant Protein CDMO was valued at US$ 59130 million in the year 2024 and is projected to reach a revised size of US$ 94330 million by 2031, growing at a CAGR of 7.0% during the forecast period.

North American market for Antibody and Recombinant Protein CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Antibody and Recombinant Protein CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The global market for Antibody and Recombinant Protein CDMO in Pharmaceutical Company is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Antibody and Recombinant Protein CDMO include Batavia Biosciences, Grifols, Cerbios-Pharma SA, HALIX, Biovian Oy, Catalent, Goodwin Biotechnology, Merck, Hangzhou Hs-biopharm, Wuxibiologics, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Antibody and Recombinant Protein CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody and Recombinant Protein CDMO.

The Antibody and Recombinant Protein CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Antibody and Recombinant Protein CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Antibody and Recombinant Protein CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

MARKET SEGMENTATION

By Company

Batavia Biosciences
Grifols
Cerbios-Pharma SA
HALIX
Biovian Oy
Catalent
Goodwin Biotechnology
Merck
Hangzhou Hs-biopharm
Wuxibiologics
Bioinnobio
Thousand Oaks Biopharmaceuticals
Eurogentec
HJB
Bibo Pharma
MabPlex International
Genscriptprobio
Vetter
Etinpro (Beijing) Co
Boehringer Ingelheim BioXcellence
Lonza
3SBio Inc
Porton

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Antibody CDMO
Recombinant Protein CDMO

Segment by Application

Pharmaceutical Company
Biotechnology Company
Generic Company

biaoTi CHAPTER OUTLINE

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antibody and Recombinant Protein CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 12: The main points and conclusions of the report.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Antibody and Recombinant Protein CDMO Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Antibody CDMO

1.2.3 Recombinant Protein CDMO

1.3 Market by Application

1.3.1 Global Antibody and Recombinant Protein CDMO Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Pharmaceutical Company

1.3.3 Biotechnology Company

1.3.4 Generic Company

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Antibody and Recombinant Protein CDMO Market Perspective (2020-2031)

2.2 Global Antibody and Recombinant Protein CDMO Growth Trends by Region

2.2.1 Global Antibody and Recombinant Protein CDMO Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Antibody and Recombinant Protein CDMO Historic Market Size by Region (2020-2025)

2.2.3 Antibody and Recombinant Protein CDMO Forecasted Market Size by Region (2026-2031)

2.3 Antibody and Recombinant Protein CDMO Market Dynamics

2.3.1 Antibody and Recombinant Protein CDMO Industry Trends

2.3.2 Antibody and Recombinant Protein CDMO Market Drivers

2.3.3 Antibody and Recombinant Protein CDMO Market Challenges

2.3.4 Antibody and Recombinant Protein CDMO Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Antibody and Recombinant Protein CDMO Players by Revenue

3.1.1 Global Top Antibody and Recombinant Protein CDMO Players by Revenue (2020-2025)

3.1.2 Global Antibody and Recombinant Protein CDMO Revenue Market Share by Players (2020-2025)

3.2 Global Antibody and Recombinant Protein CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Antibody and Recombinant Protein CDMO Revenue

3.4 Global Antibody and Recombinant Protein CDMO Market Concentration Ratio

3.4.1 Global Antibody and Recombinant Protein CDMO Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Antibody and Recombinant Protein CDMO Revenue in 2024

3.5 Global Key Players of Antibody and Recombinant Protein CDMO Head office and Area Served

3.6 Global Key Players of Antibody and Recombinant Protein CDMO, Product and Application

3.7 Global Key Players of Antibody and Recombinant Protein CDMO, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Antibody and Recombinant Protein CDMO Breakdown Data by Type

4.1 Global Antibody and Recombinant Protein CDMO Historic Market Size by Type (2020-2025)

4.2 Global Antibody and Recombinant Protein CDMO Forecasted Market Size by Type (2026-2031)

5 Antibody and Recombinant Protein CDMO Breakdown Data by Application

5.1 Global Antibody and Recombinant Protein CDMO Historic Market Size by Application (2020-2025)

5.2 Global Antibody and Recombinant Protein CDMO Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Antibody and Recombinant Protein CDMO Market Size (2020-2031)

6.2 North America Antibody and Recombinant Protein CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Antibody and Recombinant Protein CDMO Market Size by Country (2020-2025)

6.4 North America Antibody and Recombinant Protein CDMO Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Antibody and Recombinant Protein CDMO Market Size (2020-2031)

7.2 Europe Antibody and Recombinant Protein CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Antibody and Recombinant Protein CDMO Market Size by Country (2020-2025)

7.4 Europe Antibody and Recombinant Protein CDMO Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Antibody and Recombinant Protein CDMO Market Size (2020-2031)

8.2 Asia-Pacific Antibody and Recombinant Protein CDMO Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Antibody and Recombinant Protein CDMO Market Size by Region (2020-2025)

8.4 Asia-Pacific Antibody and Recombinant Protein CDMO Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Antibody and Recombinant Protein CDMO Market Size (2020-2031)

9.2 Latin America Antibody and Recombinant Protein CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Antibody and Recombinant Protein CDMO Market Size by Country (2020-2025)

9.4 Latin America Antibody and Recombinant Protein CDMO Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Antibody and Recombinant Protein CDMO Market Size (2020-2031)

10.2 Middle East & Africa Antibody and Recombinant Protein CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Antibody and Recombinant Protein CDMO Market Size by Country (2020-2025)

10.4 Middle East & Africa Antibody and Recombinant Protein CDMO Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Batavia Biosciences

11.1.1 Batavia Biosciences Company Details

11.1.2 Batavia Biosciences Business Overview

11.1.3 Batavia Biosciences Antibody and Recombinant Protein CDMO Introduction

11.1.4 Batavia Biosciences Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)

11.1.5 Batavia Biosciences Recent Development

11.2 Grifols

11.2.1 Grifols Company Details

11.2.2 Grifols Business Overview

11.2.3 Grifols Antibody and Recombinant Protein CDMO Introduction

11.2.4 Grifols Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)

11.2.5 Grifols Recent Development

11.3 Cerbios-Pharma SA

11.3.1 Cerbios-Pharma SA Company Details

11.3.2 Cerbios-Pharma SA Business Overview

11.3.3 Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Introduction

11.3.4 Cerbios-Pharma SA Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)

11.3.5 Cerbios-Pharma SA Recent Development

11.4 HALIX

11.4.1 HALIX Company Details

11.4.2 HALIX Business Overview

11.4.3 HALIX Antibody and Recombinant Protein CDMO Introduction

11.4.4 HALIX Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)

11.4.5 HALIX Recent Development

11.5 Biovian Oy

11.5.1 Biovian Oy Company Details

11.5.2 Biovian Oy Business Overview

11.5.3 Biovian Oy Antibody and Recombinant Protein CDMO Introduction

11.5.4 Biovian Oy Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)

11.5.5 Biovian Oy Recent Development

11.6 Catalent

11.6.1 Catalent Company Details

11.6.2 Catalent Business Overview

11.6.3 Catalent Antibody and Recombinant Protein CDMO Introduction

11.6.4 Catalent Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)

11.6.5 Catalent Recent Development

11.7 Goodwin Biotechnology

11.7.1 Goodwin Biotechnology Company Details

11.7.2 Goodwin Biotechnology Business Overview

11.7.3 Goodwin Biotechnology Antibody and Recombinant Protein CDMO Introduction

11.7.4 Goodwin Biotechnology Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)

11.7.5 Goodwin Biotechnology Recent Development

11.8 Merck

11.8.1 Merck Company Details

11.8.2 Merck Business Overview

11.8.3 Merck Antibody and Recombinant Protein CDMO Introduction

11.8.4 Merck Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)

11.8.5 Merck Recent Development

11.9 Hangzhou Hs-biopharm

11.9.1 Hangzhou Hs-biopharm Company Details

11.9.2 Hangzhou Hs-biopharm Business Overview

11.9.3 Hangzhou Hs-biopharm Antibody and Recombinant Protein CDMO Introduction

11.9.4 Hangzhou Hs-biopharm Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)

11.9.5 Hangzhou Hs-biopharm Recent Development

11.10 Wuxibiologics

11.10.1 Wuxibiologics Company Details

11.10.2 Wuxibiologics Business Overview

11.10.3 Wuxibiologics Antibody and Recombinant Protein CDMO Introduction

11.10.4 Wuxibiologics Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)

11.10.5 Wuxibiologics Recent Development

11.11 Bioinnobio

11.11.1 Bioinnobio Company Details

11.11.2 Bioinnobio Business Overview

11.11.3 Bioinnobio Antibody and Recombinant Protein CDMO Introduction

11.11.4 Bioinnobio Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)

11.11.5 Bioinnobio Recent Development

11.12 Thousand Oaks Biopharmaceuticals

11.12.1 Thousand Oaks Biopharmaceuticals Company Details

11.12.2 Thousand Oaks Biopharmaceuticals Business Overview

11.12.3 Thousand Oaks Biopharmaceuticals Antibody and Recombinant Protein CDMO Introduction

11.12.4 Thousand Oaks Biopharmaceuticals Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)

11.12.5 Thousand Oaks Biopharmaceuticals Recent Development

11.13 Eurogentec

11.13.1 Eurogentec Company Details

11.13.2 Eurogentec Business Overview

11.13.3 Eurogentec Antibody and Recombinant Protein CDMO Introduction

11.13.4 Eurogentec Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)

11.13.5 Eurogentec Recent Development

11.14 HJB

11.14.1 HJB Company Details

11.14.2 HJB Business Overview

11.14.3 HJB Antibody and Recombinant Protein CDMO Introduction

11.14.4 HJB Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)

11.14.5 HJB Recent Development

11.15 Bibo Pharma

11.15.1 Bibo Pharma Company Details

11.15.2 Bibo Pharma Business Overview

11.15.3 Bibo Pharma Antibody and Recombinant Protein CDMO Introduction

11.15.4 Bibo Pharma Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)

11.15.5 Bibo Pharma Recent Development

11.16 MabPlex International

11.16.1 MabPlex International Company Details

11.16.2 MabPlex International Business Overview

11.16.3 MabPlex International Antibody and Recombinant Protein CDMO Introduction

11.16.4 MabPlex International Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)

11.16.5 MabPlex International Recent Development

11.17 Genscriptprobio

11.17.1 Genscriptprobio Company Details

11.17.2 Genscriptprobio Business Overview

11.17.3 Genscriptprobio Antibody and Recombinant Protein CDMO Introduction

11.17.4 Genscriptprobio Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)

11.17.5 Genscriptprobio Recent Development

11.18 Vetter

11.18.1 Vetter Company Details

11.18.2 Vetter Business Overview

11.18.3 Vetter Antibody and Recombinant Protein CDMO Introduction

11.18.4 Vetter Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)

11.18.5 Vetter Recent Development

11.19 Etinpro (Beijing) Co

11.19.1 Etinpro (Beijing) Co Company Details

11.19.2 Etinpro (Beijing) Co Business Overview

11.19.3 Etinpro (Beijing) Co Antibody and Recombinant Protein CDMO Introduction

11.19.4 Etinpro (Beijing) Co Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)

11.19.5 Etinpro (Beijing) Co Recent Development

11.20 Boehringer Ingelheim BioXcellence

11.20.1 Boehringer Ingelheim BioXcellence Company Details

11.20.2 Boehringer Ingelheim BioXcellence Business Overview

11.20.3 Boehringer Ingelheim BioXcellence Antibody and Recombinant Protein CDMO Introduction

11.20.4 Boehringer Ingelheim BioXcellence Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)

11.20.5 Boehringer Ingelheim BioXcellence Recent Development

11.21 Lonza

11.21.1 Lonza Company Details

11.21.2 Lonza Business Overview

11.21.3 Lonza Antibody and Recombinant Protein CDMO Introduction

11.21.4 Lonza Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)

11.21.5 Lonza Recent Development

11.22 3SBio Inc

11.22.1 3SBio Inc Company Details

11.22.2 3SBio Inc Business Overview

11.22.3 3SBio Inc Antibody and Recombinant Protein CDMO Introduction

11.22.4 3SBio Inc Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)

11.22.5 3SBio Inc Recent Development

11.23 Porton

11.23.1 Porton Company Details

11.23.2 Porton Business Overview

11.23.3 Porton Antibody and Recombinant Protein CDMO Introduction

11.23.4 Porton Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)

11.23.5 Porton Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Global Antibody and Recombinant Protein CDMO Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Antibody CDMO

Table 3. Key Players of Recombinant Protein CDMO

Table 4. Global Antibody and Recombinant Protein CDMO Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 5. Global Antibody and Recombinant Protein CDMO Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Antibody and Recombinant Protein CDMO Market Size by Region (2020-2025) & (US$ Million)

Table 7. Global Antibody and Recombinant Protein CDMO Market Share by Region (2020-2025)

Table 8. Global Antibody and Recombinant Protein CDMO Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 9. Global Antibody and Recombinant Protein CDMO Market Share by Region (2026-2031)

Table 10. Antibody and Recombinant Protein CDMO Market Trends

Table 11. Antibody and Recombinant Protein CDMO Market Drivers

Table 12. Antibody and Recombinant Protein CDMO Market Challenges

Table 13. Antibody and Recombinant Protein CDMO Market Restraints

Table 14. Global Antibody and Recombinant Protein CDMO Revenue by Players (2020-2025) & (US$ Million)

Table 15. Global Antibody and Recombinant Protein CDMO Market Share by Players (2020-2025)

Table 16. Global Top Antibody and Recombinant Protein CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody and Recombinant Protein CDMO as of 2024)

Table 17. Ranking of Global Top Antibody and Recombinant Protein CDMO Companies by Revenue (US$ Million) in 2024

Table 18. Global 5 Largest Players Market Share by Antibody and Recombinant Protein CDMO Revenue (CR5 and HHI) & (2020-2025)

Table 19. Global Key Players of Antibody and Recombinant Protein CDMO, Headquarters and Area Served

Table 20. Global Key Players of Antibody and Recombinant Protein CDMO, Product and Application

Table 21. Global Key Players of Antibody and Recombinant Protein CDMO, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Antibody and Recombinant Protein CDMO Market Size by Type (2020-2025) & (US$ Million)

Table 24. Global Antibody and Recombinant Protein CDMO Revenue Market Share by Type (2020-2025)

Table 25. Global Antibody and Recombinant Protein CDMO Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 26. Global Antibody and Recombinant Protein CDMO Revenue Market Share by Type (2026-2031)

Table 27. Global Antibody and Recombinant Protein CDMO Market Size by Application (2020-2025) & (US$ Million)

Table 28. Global Antibody and Recombinant Protein CDMO Revenue Market Share by Application (2020-2025)

Table 29. Global Antibody and Recombinant Protein CDMO Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 30. Global Antibody and Recombinant Protein CDMO Revenue Market Share by Application (2026-2031)

Table 31. North America Antibody and Recombinant Protein CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 32. North America Antibody and Recombinant Protein CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 33. North America Antibody and Recombinant Protein CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 34. Europe Antibody and Recombinant Protein CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. Europe Antibody and Recombinant Protein CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 36. Europe Antibody and Recombinant Protein CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 37. Asia-Pacific Antibody and Recombinant Protein CDMO Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 38. Asia-Pacific Antibody and Recombinant Protein CDMO Market Size by Region (2020-2025) & (US$ Million)

Table 39. Asia-Pacific Antibody and Recombinant Protein CDMO Market Size by Region (2026-2031) & (US$ Million)

Table 40. Latin America Antibody and Recombinant Protein CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 41. Latin America Antibody and Recombinant Protein CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 42. Latin America Antibody and Recombinant Protein CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 43. Middle East & Africa Antibody and Recombinant Protein CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Middle East & Africa Antibody and Recombinant Protein CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 45. Middle East & Africa Antibody and Recombinant Protein CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 46. Batavia Biosciences Company Details

Table 47. Batavia Biosciences Business Overview

Table 48. Batavia Biosciences Antibody and Recombinant Protein CDMO Product

Table 49. Batavia Biosciences Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)

Table 50. Batavia Biosciences Recent Development

Table 51. Grifols Company Details

Table 52. Grifols Business Overview

Table 53. Grifols Antibody and Recombinant Protein CDMO Product

Table 54. Grifols Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)

Table 55. Grifols Recent Development

Table 56. Cerbios-Pharma SA Company Details

Table 57. Cerbios-Pharma SA Business Overview

Table 58. Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Product

Table 59. Cerbios-Pharma SA Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)

Table 60. Cerbios-Pharma SA Recent Development

Table 61. HALIX Company Details

Table 62. HALIX Business Overview

Table 63. HALIX Antibody and Recombinant Protein CDMO Product

Table 64. HALIX Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)

Table 65. HALIX Recent Development

Table 66. Biovian Oy Company Details

Table 67. Biovian Oy Business Overview

Table 68. Biovian Oy Antibody and Recombinant Protein CDMO Product

Table 69. Biovian Oy Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)

Table 70. Biovian Oy Recent Development

Table 71. Catalent Company Details

Table 72. Catalent Business Overview

Table 73. Catalent Antibody and Recombinant Protein CDMO Product

Table 74. Catalent Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)

Table 75. Catalent Recent Development

Table 76. Goodwin Biotechnology Company Details

Table 77. Goodwin Biotechnology Business Overview

Table 78. Goodwin Biotechnology Antibody and Recombinant Protein CDMO Product

Table 79. Goodwin Biotechnology Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)

Table 80. Goodwin Biotechnology Recent Development

Table 81. Merck Company Details

Table 82. Merck Business Overview

Table 83. Merck Antibody and Recombinant Protein CDMO Product

Table 84. Merck Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)

Table 85. Merck Recent Development

Table 86. Hangzhou Hs-biopharm Company Details

Table 87. Hangzhou Hs-biopharm Business Overview

Table 88. Hangzhou Hs-biopharm Antibody and Recombinant Protein CDMO Product

Table 89. Hangzhou Hs-biopharm Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)

Table 90. Hangzhou Hs-biopharm Recent Development

Table 91. Wuxibiologics Company Details

Table 92. Wuxibiologics Business Overview

Table 93. Wuxibiologics Antibody and Recombinant Protein CDMO Product

Table 94. Wuxibiologics Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)

Table 95. Wuxibiologics Recent Development

Table 96. Bioinnobio Company Details

Table 97. Bioinnobio Business Overview

Table 98. Bioinnobio Antibody and Recombinant Protein CDMO Product

Table 99. Bioinnobio Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)

Table 100. Bioinnobio Recent Development

Table 101. Thousand Oaks Biopharmaceuticals Company Details

Table 102. Thousand Oaks Biopharmaceuticals Business Overview

Table 103. Thousand Oaks Biopharmaceuticals Antibody and Recombinant Protein CDMO Product

Table 104. Thousand Oaks Biopharmaceuticals Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)

Table 105. Thousand Oaks Biopharmaceuticals Recent Development

Table 106. Eurogentec Company Details

Table 107. Eurogentec Business Overview

Table 108. Eurogentec Antibody and Recombinant Protein CDMO Product

Table 109. Eurogentec Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)

Table 110. Eurogentec Recent Development

Table 111. HJB Company Details

Table 112. HJB Business Overview

Table 113. HJB Antibody and Recombinant Protein CDMO Product

Table 114. HJB Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)

Table 115. HJB Recent Development

Table 116. Bibo Pharma Company Details

Table 117. Bibo Pharma Business Overview

Table 118. Bibo Pharma Antibody and Recombinant Protein CDMO Product

Table 119. Bibo Pharma Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)

Table 120. Bibo Pharma Recent Development

Table 121. MabPlex International Company Details

Table 122. MabPlex International Business Overview

Table 123. MabPlex International Antibody and Recombinant Protein CDMO Product

Table 124. MabPlex International Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)

Table 125. MabPlex International Recent Development

Table 126. Genscriptprobio Company Details

Table 127. Genscriptprobio Business Overview

Table 128. Genscriptprobio Antibody and Recombinant Protein CDMO Product

Table 129. Genscriptprobio Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)

Table 130. Genscriptprobio Recent Development

Table 131. Vetter Company Details

Table 132. Vetter Business Overview

Table 133. Vetter Antibody and Recombinant Protein CDMO Product

Table 134. Vetter Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)

Table 135. Vetter Recent Development

Table 136. Etinpro (Beijing) Co Company Details

Table 137. Etinpro (Beijing) Co Business Overview

Table 138. Etinpro (Beijing) Co Antibody and Recombinant Protein CDMO Product

Table 139. Etinpro (Beijing) Co Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)

Table 140. Etinpro (Beijing) Co Recent Development

Table 141. Boehringer Ingelheim BioXcellence Company Details

Table 142. Boehringer Ingelheim BioXcellence Business Overview

Table 143. Boehringer Ingelheim BioXcellence Antibody and Recombinant Protein CDMO Product

Table 144. Boehringer Ingelheim BioXcellence Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)

Table 145. Boehringer Ingelheim BioXcellence Recent Development

Table 146. Lonza Company Details

Table 147. Lonza Business Overview

Table 148. Lonza Antibody and Recombinant Protein CDMO Product

Table 149. Lonza Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)

Table 150. Lonza Recent Development

Table 151. 3SBio Inc Company Details

Table 152. 3SBio Inc Business Overview

Table 153. 3SBio Inc Antibody and Recombinant Protein CDMO Product

Table 154. 3SBio Inc Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)

Table 155. 3SBio Inc Recent Development

Table 156. Porton Company Details

Table 157. Porton Business Overview

Table 158. Porton Antibody and Recombinant Protein CDMO Product

Table 159. Porton Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)

Table 160. Porton Recent Development

Table 161. Research Programs/Design for This Report

Table 162. Key Data Information from Secondary Sources

Table 163. Key Data Information from Primary Sources

Table 164. Authors List of This Report

List of Figures

Figure 1. Antibody and Recombinant Protein CDMO Picture

Figure 2. Global Antibody and Recombinant Protein CDMO Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Antibody and Recombinant Protein CDMO Market Share by Type: 2024 VS 2031

Figure 4. Antibody CDMO Features

Figure 5. Recombinant Protein CDMO Features

Figure 6. Global Antibody and Recombinant Protein CDMO Market Size by Application (2020-2031) & (US$ Million)

Figure 7. Global Antibody and Recombinant Protein CDMO Market Share by Application: 2024 VS 2031

Figure 8. Pharmaceutical Company Case Studies

Figure 9. Biotechnology Company Case Studies

Figure 10. Generic Company Case Studies

Figure 11. Antibody and Recombinant Protein CDMO Report Years Considered

Figure 12. Global Antibody and Recombinant Protein CDMO Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 13. Global Antibody and Recombinant Protein CDMO Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global Antibody and Recombinant Protein CDMO Market Share by Region: 2024 VS 2031

Figure 15. Global Antibody and Recombinant Protein CDMO Market Share by Players in 2024

Figure 16. Global Top Antibody and Recombinant Protein CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody and Recombinant Protein CDMO as of 2024)

Figure 17. The Top 10 and 5 Players Market Share by Antibody and Recombinant Protein CDMO Revenue in 2024

Figure 18. North America Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 19. North America Antibody and Recombinant Protein CDMO Market Share by Country (2020-2031)

Figure 20. United States Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. Canada Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Europe Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Antibody and Recombinant Protein CDMO Market Share by Country (2020-2031)

Figure 24. Germany Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. France Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. U.K. Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Italy Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Russia Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Nordic Countries Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Asia-Pacific Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Antibody and Recombinant Protein CDMO Market Share by Region (2020-2031)

Figure 32. China Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Japan Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. South Korea Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Southeast Asia Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. India Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Australia Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Latin America Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Antibody and Recombinant Protein CDMO Market Share by Country (2020-2031)

Figure 40. Mexico Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Brazil Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Middle East & Africa Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Antibody and Recombinant Protein CDMO Market Share by Country (2020-2031)

Figure 44. Turkey Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Saudi Arabia Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. UAE Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Batavia Biosciences Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)

Figure 48. Grifols Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)

Figure 49. Cerbios-Pharma SA Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)

Figure 50. HALIX Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)

Figure 51. Biovian Oy Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)

Figure 52. Catalent Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)

Figure 53. Goodwin Biotechnology Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)

Figure 54. Merck Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)

Figure 55. Hangzhou Hs-biopharm Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)

Figure 56. Wuxibiologics Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)

Figure 57. Bioinnobio Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)

Figure 58. Thousand Oaks Biopharmaceuticals Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)

Figure 59. Eurogentec Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)

Figure 60. HJB Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)

Figure 61. Bibo Pharma Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)

Figure 62. MabPlex International Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)

Figure 63. Genscriptprobio Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)

Figure 64. Vetter Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)

Figure 65. Etinpro (Beijing) Co Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)

Figure 66. Boehringer Ingelheim BioXcellence Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)

Figure 67. Lonza Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)

Figure 68. 3SBio Inc Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)

Figure 69. Porton Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)

Figure 70. Bottom-up and Top-down Approaches for This Report

Figure 71. Data Triangulation

Figure 72. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which region is expected to have the highest market share? zhanKai

For each regional market, the report conducted in-depth comparative analysis from multiple dimensions such as market size, 7% compound annual growth rate, market demand, industrial structure, policy environment, and the layout of major enterprises. It systematically summarized the market characteristics and competitive environment of different regions. At the same time, it also focused on analyzing the demand structure, market growth drivers, and investment environment of each region, providing valuable references for enterprises to identify key regional markets, formulate global market layouts and sales strategies.

Which companies rank high in the global Antibody and Recombinant Protein CDMO market? shouQi

What is the annual compound growth rate of the global Antibody and Recombinant Protein CDMO market size from 2025 to 2031? shouQi

What was the global market size of Antibody and Recombinant Protein CDMO in 2031? shouQi

What was the global market size of Antibody and Recombinant Protein CDMO in 2025? shouQi

Related Reports

Antibody and Recombinant Protein CDMO- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Antibody and Recombinant Protein CDMO was estimated to be worth US$ 59130 million in 2024 and is forecast to a readjusted size of US$ 94330 million by 2031 with a CAGR of 7.0% during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 149
USD 3950.00
(Single User License)
Global Antibody and Recombinant Protein CDMO Market Insights, Forecast to 2030
Market Analysis and Insights: Global Antibody and Recombinant Protein CDMO Market
Published Date: 2024-04-12
Pages: 129
USD 4900.00
(Single User License)
Global Antibody and Recombinant Protein CDMO Market Research Report 2024
The global Antibody and Recombinant Protein CDMO market was valued at US$ 51310 million in 2023 and is anticipated to reach US$ 83480 million by 2030, witnessing a CAGR of 7.0% during the forecast period 2024-2030.
Published Date: 2024-01-12
Pages: 106
USD 2900.00
(Single User License)
Antibody and Recombinant Protein CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
The global market for Antibody and Recombinant Protein CDMO was estimated to be worth US$ 51310 million in 2023 and is forecast to a readjusted size of US$ 83480 million by 2030 with a CAGR of 7.0% during the forecast period 2024-2030
Published Date: 2024-01-08
Pages: 156
USD 3950.00
(Single User License)

Antibody and Recombinant Protein CDMO- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Antibody and Recombinant Protein CDMO was estimated to be worth US$ 59130 million in 2024 and is forecast to a readjusted size of US$ 94330 million by 2031 with a CAGR of 7.0% during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 149
USD 3950.00 (Single User License)
Global Antibody and Recombinant Protein CDMO Market Insights, Forecast to 2030
Market Analysis and Insights: Global Antibody and Recombinant Protein CDMO Market
Published: 2024-04-12
Pages: 129
USD 4900.00 (Single User License)
Global Antibody and Recombinant Protein CDMO Market Research Report 2024
The global Antibody and Recombinant Protein CDMO market was valued at US$ 51310 million in 2023 and is anticipated to reach US$ 83480 million by 2030, witnessing a CAGR of 7.0% during the forecast period 2024-2030.
Published: 2024-01-12
Pages: 106
USD 2900.00 (Single User License)
Antibody and Recombinant Protein CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
The global market for Antibody and Recombinant Protein CDMO was estimated to be worth US$ 51310 million in 2023 and is forecast to a readjusted size of US$ 83480 million by 2030 with a CAGR of 7.0% during the forecast period 2024-2030
Published: 2024-01-08
Pages: 156
USD 3950.00 (Single User License)